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Differential Effects of Granulocyte-Macrophage Colony-Stimulating Factor and 
Granulocyte Colony-Stimulating Factor in Children With 
Severe Congenital Neutropenia 
By Karl Welte, Cornelia Zeidler, Alfred Reiter, Wolfgang Muller: Edelgard  Odenwald, Lawrence Souza, 
and Hansjorg Riehm 
Severe  congenital  neutropenia  (SCN)  is  a  disorder  of 
myelopoiesis characterized by severe neutropenia second- 
ary to  a maturational arrest at the level of promyelocytes. 
We  treated  five  patients  with  SCN  with  recombinant 
human granulocyte-macrophage colony-stimulating factor 
(rhGM-CSF) for 42 days and subsequently, between 1  and 3 
months later, with rhG-CSF for 142 days.  The objective 
was to evaluate the safety and ability of these factors to 
elicit a neutrophil response. rhGM-CSF was administered 
at a dose of 3  to 30  pglkgld (30  to 60 minutes,  intrave- 
nously). In all patients, a specific, dose-dependent increase 
in the absolute granulocyte counts was observed.  How- 
ever, in four patients this increase was due to  an increase 
in eosinophils,  and in only one patient it was due to an 
increase in the absolute neutrophil counts (ANC). Subse- 
EVERE CONGENITAL neutropenia (SCN;  Kostmann  S  Syndrome), a disorder of myelopoiesis, is characterized 
by an impairment of myeloid differentiation in bone marrow 
with absolute neutrophil counts (ANC) below  200//.4L in 
blood  of  affected patients.'-17 This disorder  was  first  de- 
scribed by Kostmann in 1956.I.'  Patients with SCN experi- 
ence frequent episodes of fever, pneumonitis, skin infections, 
and perianal and liver abscesses, usually beginning in early 
infancy and often leading to fatal infections despite antibiotic 
therapy. Bone marrow morphologic findings in these patients 
have been variable, but a maturation arrest of myelopoiesis 
at  the promyelocyte stage is usually  The promyelo- 
cytes are  frequently morphologically atypical with vacuoliza- 
tion and atypical nuclei. Several methods of  therapy have 
been attempted in these patients including white cell transfu- 
sions,  corticosteroids,  vitamin-B6,  lithi~m,'~.'~  androgens, 
and bone  marrow  transplantation  (BMT). To date, only 
BMT has resulted in partial or complete correction  of  the 
neutropenia.I6*l7 
The etiology of SCN  is unknown. There is no evidence for 
serum  inhibitors  or  anti-neutrophil  antibodies  in  these 
patients."  Some investigators  described  ultrastructural le- 
sions  in  cultured  neutrophils  from  abnormal  neutrophil 
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quently, all patients received rhG-CSF at a dose of 3  to 15 
pg/kg/d subcutaneously. In contrast to rhGM-CSF treat- 
ment,  all five patients responded to rhG-CSF during the 
first 6  weeks of treatment with an increase in the ANC to 
above  l,OoO/pL.  The level of ANC  could be maintained 
during maintenance  treatment. In one patient, the increase 
in ANC was associated with an improvement of a severe 
pneumonitis caused by Peptostreptococcus and resistant 
to antibiotic  treatment.  No  severe  bacterial  infections 
occurred in any of the patients during CSF treatment. All 
patients tolerated rhGM-CSF and rhG-CSF treatment with- 
out  severe side effects. These results demonstrate the 
beneficial  effect of rhG-CSF in SCN patients. 
0 1990 by The American Society of Hematology. 
c~lonies.~."  Deficiency of  colony  stimulating factor (CSF) 
production has been suggested:'  but the levels of production 
of specific CSFs have not been evaluated. 
Hematopoietic  progenitor cell assays (colony-forming unit- 
granulocyte macrophage  [CFU-GM]) performed on bone 
marrow cells from SCN  patients in the presence of undefined 
growth factors (leukocyte feeder layers or spleen conditioned 
medium) have been reported to generate variable numbers of 
neutrophil  Recently  granulocyte  macrophage 
CSF (GM-CSF) and granulocyte CSF (G-CSF) have been 
purified, molecularly cloned, and expressed as recombinant 
proteins.  Both  have  been  shown  to  be potent stimuli for 
normal myeloid proliferation and differentiation in vitro and 
in vivo.''-3o In the presence of recombinant human GM-CSF 
(rhGM-CSF), CFU-GM assays  demonstrated  mainly the 
growth of  monocyte/macrophage  and eosinophil  colonies, 
and in the presence of rhG-CSF predominantly monocyte/ 
macrophage colonies. The absolute number of colonies was 
diminished compared with normal controls. The growth of 
neutrophil colonies with  either factor could not be clearly 
shown (Welte K.,  unpublished observation, April 1989). 
The first  clinical  trial  investigated  GM-CSF in  SCN 
patients; because only 1 of 5 patients showed any increase in 
circulating neutrophils,  we  subsequently  initiated a study 
with G-CSF. The objectives of these studies were to deter- 
mine and compare the safety and biologic effectiveness of 
these cytokines in the treatment of SCN  to design an optimal 
therapy for this fatal disease. To test whether the myeloid 
growth factors could  generate neutrophils in vivo,  it was 
necessary to design the appropriate clinical trials since there 
were no preclinical models for this disease. 
MATERIALS AND METHODS 
Five patients with SCN were treated in a phase 1/11 clinical trial 
with rhGM-CSF and subsequently, between  1 to 3 months later, 
with  rhG-CSF. The diagnosis  of  SCN  was  established on  the 
following basis:  (1)  absence of  blood  neutrophils (<200/pL);  (2) 
maturation arrest in the neutrophil  lineage at the promyelocyte stage 
with  morphologic  abnormalities; and  (3) clinical onset of  severe 
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bacterial infections during the first 12 months of life. In general, this 
patient  population  also  experiences  absolute  increases  in  both 
monocyte and eosinophil counts (Table 1). 
Study Design 
The objectives of  the  studies  were:  (1)  to assess  the  safety 
tolerance, and toxicity of multiple doses of rhGM-CSF or rhG-CSF 
administered  daily;  (2)  to  assess  the  effects of  rhGM-CSF  or 
rhG-CSF on myeloid maturation and blood neutropenia; and (3) to 
observe the effects of  these therapies  on the occurrence of  severe 
infections. 
Inclusion and Exclusion Criteria 
Patients had to fulfill all of the following criteria to be eligible for 
study admission: (1)  diagnosis of severe congenital neutropenia (see 
criteria above) and age above 1 month; (2) normal kidney and liver 
functions as judged  by  creatinine,  bilirubin,  transaminases,  and 
coagulation function; (3) normal electrocardiogram (ECG); (4) not 
on  experimental  therapy,  chemotherapy,  hormonal  therapy,  or 
immunotherapy;  (5)  absence of  serious infections uncontrolled on 
antibiotic therapy or requiring white cell transfusion; (6)  absence of 
anti-neutrophil  antibodies (alto-antibodies); and (7)  a written  in- 
formed consent from either the patient or parent before treatment. 
Re-study evaluation included medical history, physical examina- 
tion, chest x-ray, ECG, sonography of liver and spleen, bone marrow 
aspiration  for morphology and progenitor assays (CFU-GM),  re- 
peated blood counts  on at least 2 days before treatment, liver and 
renal  function  parameter  by  serum  chemistry,  and  C-reactive 
protein (CRP). 
These clinical trials were approved by the Ethical Committee on 
the  Use  of  Human  Subjects  in  Research  at the  Medizinische 
Hochschule Hannover, FRG, and informed consent was obtained 
before entry into the study. 
General Treatment Plan 
rhGM-CSF was administered intravenously (IV) 
at doses of 3, 10, and 30 pg/kg/d.  All patients were started with 3 
pg/kg/d  rhGM-CSF (30 to 60  minutes IV infusion) for 14 days. If 
no response was seen by  day  14 at each dose level, patients were 
moved  to  the  next  dose  level  (10  pg/kg/d  and  30  pg/kg/d, 
respectively) for 14 days. If after 14 days at the maximal dose no 
response was  observed  (no increase  in  ANC),  the  therapy  was 
discontinued. A complete response was defined as an ANC greater 
than 1,000 cells/mm3. One month after ending the study, one patient 
(no.  1) was treated subsequently with 10 pg/kg/d  of rhGM-CSF as 
continuous infusion for 4 weeks and received subcutaneous adminis- 
tration for  1 additional week. rhGM-CSF, expressed in yeast, was 
purified to homogeneity and had a specific activity of 5 x  lo7  U/mg 
protein.''  It was endotoxin-free as  judged by the rabbit pyrogen test 
rhGA4-CSF. 
and by  the limulus amebocyte lysate assay. rhGM-CSF was pro- 
vided by Behringwerke AG, Marburg, FRG. 
Because no response to rhGM-CSF was seen in 4 of  5 
patients, a study with rhG-CSF was initiated in these same patients. 
As in the previous trial, all patients were started with 3 pg/kg/d, but 
the rhG-CSF was administered subcutaneously (s.c.).  If no response 
was observed by day 14, patients were moved to the next dose level (5 
pg/kg/d) and then by increments of 5 pg/kg/d to a maximal dose of 
15 pg/kg/d  given as two equal fractions.  Patients with complete 
responses  at  the  end  of  the  dose  escalation  were  eligible  for 
enrollment into a maintenance treatment. rhG-CSF was provided by 
Amgen (Thousand Oaks, CA). It was expressed in Escherichia coli 
and purified to homogeneity. The rhG-CSF had a specific activity of 
approximately  10'  U/mg  protein,26 and  was  endotoxin-free  as 
judged by the rabbit pyrogen test and the limulus amebocyte lysate 
assay. 
rhG-CSF. 
Case Reports 
Patient 1.  The diagnosis of SCN  was made at  age 4 months in a 
2-year-old girl. Since then she has experienced recurrent enteritis, 
bronchitis, staphylodermatitis, and failure to thrive. Despite antibi- 
otic prophylaxis, she developed recurrent bacterial  lung infiltrates 
caused by  anaerobic Peptostreptococcus. which led to respiratory 
distress before entering the study. 
A 1-year-old boy was diagnosed at age 10 months and 
had been experiencing recurrent otitis media requiring tympanot- 
omy and continuous antibiotic treatment with amoxycillin. At the 
beginning of  the  GM-CSF treatment  the patient  presented  with 
subacute otitis and pneumonitis. 
Diagnosis  of  SCN was  made  in  this  patient  at 
approximately  1 year  of  age.  This  19-year-old man  had  a  long 
history of recurrent bacterial skin infections (predominantly Staphy- 
lococcus), mucosal abscesses (eg, anal abscesses, gingivostomatitis), 
and  repeated  episodes  of  pneumonitis,  enteritis,  and  tonsillitis 
throughout his life that required him to be.  hospitalized frequently. 
He suffered from severe gingivitis at the beginning of the rhGM- 
CSF  study. 
Patient 4.  A 3-year-old girl presented with bacterial and fungal 
infections of  the lung, skin, and mucosa beginning during her first 
months of  life. She was repeatedly hospitalized because of  severe 
pneumonitis. She had  no acute infections at the beginning of  the 
GM-CSF trial. 
Patient 5.  A 9-year-old girl suffered from recurrent episodes of 
severe bacterial and fungal infections of the lungs, skin, and liver 
from her first months of life. The diagnosis of SCN  was made at age 
1 month. At the age of  4 years, a lobectomy of the right lower lung 
and a  partial hepatectomy had to be performed in the course of 
severe liver and lung abscesses. She had no severe infections at the 
beginning of the rhGM-CSF treatment. 
All of  the patients in the studies received prophylactic antibiotic 
Patient 2. 
Patient  3. 
Table 1.  Patients' Hematologic Characteristics Before CSF Treatment 
Patient 
No. 
1 
2 
3 
4 
5 
Bone Marrow  Blood 
Promyel  MY&  WBC  Neu  Eo  Bas  Mono  Lvwh  Plat  Hb 
%  %  (~10-3)  (%)  (961  (%)  (%I  (%I  (X 10-31  (e/%) 
2  1  4.5  0  6  3  18  73  282  6.6 
11  0  6.1  0  12  0  18  70  43  1  11.0 
5  1  8.0  0  7  0  37  41  23 1  14.0 
25  6  2.2  1  0  1  40  55  218  12.5 
13  1  3.1  1  13  5  19  60  465  8.0 
Abbreviations: promyel.  promyelocytes; myel,  myelocytes; WBC.  white blood  cells;  Neu,  neutrophils: Eo,  eosinophils; Bas,  basophils; Mono, 
monocytes/macrophages: Lymph, lymphocytes; Plat, platelets; Hb, hemoglobin. 1058  WELTE ET  AL 
therapy with co-Trimoxazal,  amoxicillin, rifampicin, or flucloxacil- 
lin. Laboratory examinations, including  differential blood  counts 
and percentage of  promyelocytes in the bone marrow before rhGM- 
CSF study, are listed in Table 1. 
Patient Monitoring 
During the CSF treatment periods, the patients were evaluated 
daily for vital signs, temperature, and complete blood  cell counts; 
and weekly  by  liver  and renal functional tests, electrolytes, and 
serum protein  levels,  including immunoglobulins.  Bone  marrow 
aspirations were performed at days 0, 14, and 42 of  each trial, and 
bone  marrow  cellularity and morphology were examined by  light 
microscopy. 
CRP  Assay 
The CRP was  determined in  the  serum of  patients using  an 
enzyme-immunoassay (Merck, Darmstadt, FRG). The normal con- 
centration in healthy volunteers  is below 9 mg/L.3' 
RESULTS 
Effects of rhGM-CSF on Blood Cells 
The effects of rhGM-CSF (3 to 30 pg/kg/d IV) are shown 
in Fig 1A. As can be seen, infusion of rhGM-CSF resulted in 
an increase in the number of  blood neutrophils  (ANC) in 
only one patient (no. 4), but had no effect on the other four 
patients. The ANC in patient no. 4  increased  at day 9 to 
10,296/pL,  then  oscillated  at levels  between  1,000  and 
6,OOO/pL.  In contrast, the response of blood eosinophils to 
this  treatment  was  quite  different.  In  the four  patients 
without  an increase in neutrophils,  the absolute number of 
eosinophils  (AEoC) increased from values below  1 ,OOO/pL 
to  3,200  to  5,7OO/pL  (Table  2). The increase  in  AEoC 
occurred in a dose-dependent  manner (data not shown). In 
contrast, no increase in AEoC was observed in patient no. 4. 
Absolute monocyte counts (AMC) increased two- to sixfold 
in all patients except for patient no. 4 (Table 2). Other blood 
cells such as erythrocytes, platelets, or lymphocytes did not 
change significantly during rhGM-CSF treatment (data not 
shown). 
To test whether the mode or route of  administration of 
rhGM-CSF  changed  the quality  of  response,  we  subse- 
quently treated one patient (patient no. 1) 1 month after the 
last dose of  rhGM-CSF with  10 pg/kg/d  rhGM-CSF by 
continuous infusion for 4 weeks, and thereafter with subcuta- 
neous administration at 10 pg/kg/d for 1 week. As shown in 
Table 3, neither  method of  administration  resulted  in  an 
increase in the ANC, but AEoC incrased to 23,814/pL. 
Eflects of rhG-CSF on Blood Cells 
In contrast to  rhGM-CSF treatment, rhG-CSF  administra- 
tion in all five patients led to an increase in ANC to levels 
greater  than  l,OOO/pL  (Fig  1B). The dosages  needed  to 
achieve an ANC of  1,000 was 3 pglkgld in three patients 
(nos. 3,4, and 5j  and 10 pg/kg/d in two patients (nos. 1 and 
2).  The dosage  required  to  maintain  an ANC of  above 
l,OOO/pL  was different  in  each patient.  Patient no.  4 re- 
quired 3 pg/kg/d; patient no, 3 required 5 pg/kg/d;  patient 
no.  2  required  10  pg/kg/d;  patient  no.  1  required  15 
pg/kg/d. In patient no. 5, the rhG-CSF treatment had to be 
stopped after 12 days due to a cutaneous necrotic vasculitis, 
possibly related to the dramatic increase of neutrophils (see 
below). The best maintenance dose for this patient has yet to 
be determined. 
The AEoC was not significantly augmented in all patients. 
Comparing only day 0 with days 39  and 40 of treatment, 
patient no. 3 appeared to increase the AEoC fivefold from 
baseline  (Table 2). However,  an inspection  of  the whole 
treatment period showed an oscillation between 100 and 800 
eosinophils/pL in this patient. With the exception of patients 
no.  4  and  5, the AMC increased  two-to-eightfold  in  all 
patients during rhG-CSF treatment (Table 2). Patient no. 3 
started the rhG-CSF treatment  with  an excessively  high 
number of  AMC (3,438/pL) that increased  to 24,8OO/pL 
during treatment (Table 2). 
rhG-CSF Maintenance Therapy 
Because  all  patients  responded  to  rhG-CSF  with  an 
increase in ANC, we continued the therapy with rhG-CSF 
after day 42 at these dose levels (3 to 15 pg/kg/d; see above) 
necessary to maintain an ANC of above 1,00O/pL, with the 
exception of patient no.  5 who was maintained at an ANC 
between  200  and  800/pL.  The  ANCs  that  have  been 
maintained during the following  100 days (day 43  to day 
142 of rhG-CSF treatment) are shown in Fig 1C. 
Bone Marrow 
The number of  promyelocytes before and during rhGM- 
CSF treatment did not change significantly in four patients 
(nos.  1,  2,  3,  and  5).  During  rhG-CSF  treatment,  two 
patients (nos. 1 and 2) showed increases of the promyelocyte 
percentages in the first 6 weeks of rhG-CSF treatment: from 
2% to 12%  in patient no.  1, and 9% to 14% in patient no. 2. 
Patient no.  4 started with 25% promyelocytes  before  any 
treatment, developed up to 40%  promyelocytes during GM- 
CSF treatment, and  went  back to 24% after 6 weeks  of 
rhG-CSF treatment. 
Clinical Responses 
Before  rhGM-CSF treatment,  all  patients  experienced 
recurrent  bacterial  and fungal infections.  During  rhGM- 
CSF treatment, no episodes of new severe bacterial infections 
occurred. Two patients resolved their gingivostomatitis. How- 
ever, patient no. l, who suffered from severe lung infiltrates 
caused by anaerobic Peptostreptococcus,  did not show im- 
provement  in  pulmonary status. In one patient  (no.  5), a 
Staphylococcus aureus  induced  paronychia  developed  de- 
spite rhGM-CSF  treatment. 
In contrast, during rhG-CSF treatment, the Peptostrepto- 
coccus-caused lung infiltrates  in patient no.  1 dramatically 
resolved within 6 weeks of  therapy (Fig 2). In the interval 
between rhGM-CSF and rhG-CSF treatment she received 6 
weeks of IV antibiotics under a hospital setting. During the 
first 4 weeks of rhG-CSF treatment, her pulmonary situation 
resolved to such a degree that the IV antibiotics could be 
replaced by prophylactic oral antibiotic therapy. This resolu- 
tion appeared in association with the increase in neutrophils 
(Fig  1). The number of  days with temperatures of  above ZOO0 - -3-10-307  2000  2000 
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ANC in patient nos. 1  through 5 during (A) rhGM-CSF treatment;  (B) the first 42  days of rhG-CSF treatment: and IC) rhG-CSF 
maintenance  therapy. Data from patient no. 1  are shown in row 1,  patient no. 2  in row  2.  patient no. 3  in  row 3. patient no. 4 in row  4. and 
patient no.  5 in row 5.  The dosages (pg/kg/d)  of rhGM-CSF or rhG-CSF are shown on the top of row 1 for patient no. 1. Dosages for 
patients nos. 2 through 5 are only pointed out in case  of differences to patient no. 1 (3  = 3  I.rg/kg/d: 10 = 10 pg/kg/d:  etch Asterisks 
denote days when cutaneous  necrotic  vasculitis occurred (see  patient no. 5). 
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fable 2.  AEoC and AMC Before and During CSF Treatment 
Trertment  IhGM-CSF  IhG-CSC 
--  ~- 
DwO  Dm39140  QwO  Qm39I40 
AEoC  f x 10  ’lpL)  Petmnt 
1  0.5  3.6  1.1  1.7 
2  0.7  3.2  0.8  1.4 
3  0.2  3.5  0.1  0.6 
4  0  0  0  0 
5  0.4  5.7  0.4  0.5 
AMC f x 10  ’IpL) 
1  0.3  1.9  0.7  1.6 
2  1.1  5.7  1.2  5.3 
3  6.6  11.9  3.4  24.8 
4  0.4  0.3  1.2  0.5 
5  0.6  1.6  0.9  0.8 
38.OOC  were 55  of 162 before rhG-CSF  therapy. 7 during the 
first 4 weeks of  therapy. and no additional febrile episodes 
within  the subsequent  observation  period of  I00 days.  No 
new bacterial infections have developed  in this patient. The 
other four patients were without bacterial infections through- 
out  the  rhG-CSF  treatment  period  (up to  day  143)  as 
compared  with  at least  one severe  bacterial  infection  per 
patient in the 6 months before CSF  therapy. 
An important clinical parameter for the evaluation of any 
acute infections.  the CRP” dccreased during rhGM-CSF 
therapy and normalized during rhG-CSF therapy in patient 
no.  I. The values.  shown as mean  and standard deviation 
(n = number of indepcndent determinations), are as follows: 
before  rhGM-CSF therapy.  117  mg/L  (n = I);  during 
rhGM-CSF treatment.  84 (+/- 18) mg/L  (n = 9); be- 
tween  rhGM-CSF and rhG-CSF treatment.  82 ( + / -  33) 
mg/l.  (n = IO);  during  the  first  4  weeks  of  rhG-CSF 
treatment.  80  (+/-25)  mg/L  (n  5). and on  days  29 
through  143 of  rhG-CSF treatment.  17  (~/-9)  mg/L 
(n = IO). The normal range is 0 to 9 mg/L. In the other four 
patients the CRP was not elevated signifcantly  throughout 
GM-CSF or G-CSF therapy. 
Table 3.  Effects of Cominubus Infusion (days  1 through 28) and 
Svbcutanwus Administration (days 29 through 361 of rhGM-CSF 
(10pglkgld)  in Patient No. 1 
Day  WBC  ANC  A€&  AB&  AMC  AlC 
cdls x  10 ’ 
0  6.8  0  0.4  0.1  1.6  4.7 
14  29.4  0  23.8  0.1  0.9  4.6 
28  26.8  0  20.1  0.3  0.8  5.6 
35  26.9  0  22.6  0.2  0.2  3.9 
Patmt  was penested  mth  rhGM-CSF accordmg to Flg 1. Thare WM  a 
Cy.  neatmeot-tree  ~ntsrvsl  d  1 mmth  between day 42  of rhGM-CSF fFtg 
1) end day 1 d  contmt“  infusron. 
Abbrsnstms:  WBC.  whrte  bbod cdls:  ANC.  absolute  neunophtl 
count:  AEoC.  absolute  eOStnOOhll  count:  ABswC.  absolute  basoohtl 
I 
c 
Fig 2.  X-ray pkturea from patient no. 1 at days  21 and 43 of 
rhG-CSF treatment. 
Side Eflecrs of Trearnient 
Roth rhGM-CSF and rhG-CSF were tolerated well by all 
patients. During the highest dose level of  rhGM-CSF trcat- 
ment  (30 pg/kg/d).  a  mild  local  phlebitis  at the  site of 
infusion of  rhGM-CSF  was observed in all patients. The only 
serious side effect occurred  in one patient during rhG-CSF 
treatment. Patient no. 5 suffered from a cutaneous necroti7- 
ing vasculitis (1eukocytocl;istic vasculitis) on both lower legs 
at day I2 of rhG-CSF treatment (3  pg/kg/d) when the ANC 
was 2,68O/pl..  The rhG-CSF was discontinued  for  IO days 
and then rcstartcd at 0.3  pg/kg/d for 2 weeks. doubled to 0.6 
pg/kg/d  for the next 2 weeks, and then raised to  I  pg/kg/d 
for 2 weeks. When the dose was escalated to 2 pg/kg/d.  the 
ANC again  rose  above  I,OOO/p1. and  the vasculitis reap 
pearcd at the same site. The rhG-CSF treatment was again 
discontinued  for  I  week.  and  restarted  at  a  dose  of  0.6 
pg/kg/d  for  2  weeks,  then  raised  to  0.8  pg/kg/d  for 
maintenance therapy. At this dose, patient no. 5 has ;in ANC 
of approximately 200 to 800/pl.  without further recurrence 
of the vasculitis. 
The serum alkaline phosphatase levels increased  in one 
patient with 285 U/I. (before rhG-CSF) to441 U/I. (day 42 
count:  AMC.  &solute  mOnOCyte  -1:  ALC.  absolute  mphocyte 
counts. 
of  rhG-CSF treatment). and remained unchanged within the 
normal  range  in  four  patients.  Liver  and  renal  functions GM-CSF  AND G-CSF  IN CONGENITAL NEUTROPENIA  1061 
remained normal. Side effects reported for rhGM-CSF or 
rhG-CSF trials, such as bone pain or fever, did not occur in 
these patients. 
DISCUSSION 
In this study, five patients with severe congenital neutrope- 
nia  (Kostmann Syndrome) were treated for  42 days with 
rhGM-CSF, after an interval of  1 to 3 months these patients 
were also treated with rhG-CSF. Therapy with rhGM-CSF 
resulted  in  increased  numbers  of  granulocytes consisting 
predominantly of eosinophils in 4 of the 5 patients treated. In 
only one patient, there was a significant increase of  neutro- 
phils. The small number of patients studied does not allow US 
to  make  definite statements  regarding  the  percentage  of 
patients who may respond to rhGM-CSF with a increase of 
neutrophils. The clinical picture of patients receiving rhGM- 
CSF was improved as measured by the resolution of gingivos- 
tomatitis in  two patients. In addition, there were no severe 
bacterial  infections in the patients  during  this short time 
period.  This  suggests  that  high  numbers  of  eosinophils 
activated by  rhGM-CSF may be of clinical benefit. In vitro, 
rhGM-CSF is a potent stimulator of eosinophil functions.’’ 
In contrast to rhGM-CSF, rhG-CSF induced an increase 
of blood neutrophils in all five patients. The dose necessary to 
reach and maintain an ANC of above l,OOO/pL  varied from 
patient to patient and ranged between 3 and 15 pg/kg/d.  The 
neutrophils in  the  rhG-CSF-treated  patients  had  normal 
functional activities as judged by  clinical parameters. In one 
patient there was a resolution of  a severe bacterial infiltrate 
caused by Peptostreptococcus,  in the left lung resistant to IV 
antibiotic  treatment.  Additional  SCN patients  have  been 
treated  with  rhG-CSF by  Bonilla et  showing similar 
increases in peripheral neutrophil counts. 
To test whether the route of  administration was responsi- 
ble for the lack of  neutrophil responses to rhGM-CSF, one 
patient  (no.  1)  received  additional treatment with rhGM- 
CSF for 4 weeks as a continuous infusion, and subsequently 
for 1 week as a subcutaneous infusion. During this treatment 
period the eosinophils increased to up to 25,OOO/pL, demon- 
strating  the  potent  biologic activities of  rhGM-CSF,  yet 
there was still no increase in the ANC. In addition, the 30- to 
60-minute infusion of  rhGM-CSF was completely sufficient 
to dramatically  increase the ANC in  one patient  (no. 4). 
These data demonstrate that it is very unlikely that the route 
of administration of rhGM-CSF was responsible for the lack 
of increases in ANC in 4 of  5 patients. 
The lack of  neutrophil production in the majority of  the 
SCN patients treated with rhGM-CSF is also in contrast to 
the clinical trials with rhGM-CSF in patients with myelodys- 
plastic  syndromes, acquired  immunodeficiency  syndrome 
(AIDS), neutropenia after chemotherapy, and patients hav- 
ing undergone autologous BMT, where substantial increases 
in ANC have been  In addition, in patients with 
idiopathic neutropenia, treatment with rhGM-CSF resulted 
in a substantial increase in ANC associated with a dramatic 
clinical improvement (Welte K., unpublished observations, 
December  1988). This  indicates  that  SCN must  have  a 
different pathophysiology as compared with idiopathic neu- 
tropenia. 
Recently, Sonoda et a134 showed that GM-CSF used in 
vitro in serum-free cultures of normal enriched hematopoetic 
progenitor cells is unable to generate neutrophil colonies on 
its own. However, this same study demonstrates that G-CSF 
under  the same  conditions can  generate  some neutrophil 
colonies, and that the production of these colonies in vitro is 
enhanced by  the combination of  GM-CSF and G-CSF. The 
investigators hypothesize that the primary targets of  GM- 
CSF are early  stage progenitors rather  than  cells in  the 
terminal process of  mat~ration.~~  In view of  these recently 
published  data, the hypotheses for the lack of  neutrophil 
production in congenital neutropenia patients treated with 
rhGM-CSF could be as follows: if late neutrophil precursors 
respond only to G-CSF, than a defect in G-CSF production 
and/or a defective response of  these cells to G-CSF could 
explain the disease. A defective G-CSF production does not 
seem likely in light of new data which show that serum from 
these patients contain normal or elevated levels of G-CSF, as 
judged  by  Western  blot  analysis  and  in  vitro  bioassays 
(Mempel K., Zeidler C., Menzel T., Welte K., manuscript in 
preparation). The second, more attractive, hypothesis for the 
genetic disposition affecting these patients could involve  a 
defective G-CSF response. The variations from patient to 
patient in response to rhG-CSF to achieve an ANC of  1,000 
p/L  and  the  need  for  pharmocologic dosing  (3  to  15 
pg/kg/d)  to reach  this low  but  adequate neutrophil  level 
support this hypothesis. A genetic defect in the GM-CSF 
response is not very likely since it would have to be restricted 
to the neutrophil lineage. 
There were minimal side effects from both rhGM-CSF 
and rhG-CSF treatment  in  these patients.  At the highest 
dose  of  rhGM-CSF  (30  pg/kg/d),  we  observed  a  mild 
phlebitis  at the  site  of  infusion  in  all  patients.  During 
rhG-CSF treatment, only one patient experienced significant 
side effects. This patient  suffered from cutaneous necrotic 
vasculitis which on immuno-histologic examination showed 
the presence of  inflammatory  infiltrates  into  the  area  of 
superficial small vessels. Mononuclear cells, eosinophils, and 
neutrophils  were  detected.  Because  this  side  effect  was 
clearly associated with an ANC of  above 1,00O/pL and not 
with the dose of  rhG-CSF, the relatively increased numbers 
of  neutrophils  have  to  be  considered  as  cause  for  the 
vasculitis. The pathogenetic mechanisms of  the vasculitis 
could be  explained by  infiltration of  inflamed vessel  walls 
with  neutrophils  and  mononuclear  cells,  and  subsequent 
disruption of the small superficial cutaneous vessels. Deposits 
of immunoglobulins, complement components, or circulating 
unspecific immune complexes, all compensatively  elevated in 
the blood of  this patient, may have potentiated this process. 
The  role  of  neutrophils  in  necrotic  vasculitis  has  been 
reported  and  is  considered as  one  of  the  major  causing 
agents.35  The sudden increase in neutrophils in a patient who 
has adjusted to the absence of neutrophils for 10 years could 
easily explain this side effect. 
Formal proof of clinical efficacy in this patient population 
with  either  CSF  will  require  long-term  examination  of 1062  WELTE  ET  AL 
patients currently on study and/or phase I11 investigation. 
However, the dramatic response in one patient with severe 
bacterial pulmonary infiltrates can only be explained by the 
presence of sufficient numbers of neutrophils. 
These  findings  demonstrate that rhG-CSF is  the most 
promising Of all available treatments for SCN. The COrreC- 
tion of  neutropenia  with resultant improvement  of Clinical 
status can  dramatically change  the high  morbidity,  and 
therefore the quality of  life, in these patients. The risk of 
mortality from severe bacterial infections will most likely be 
diminished. 
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